Basic Information
Menactra®, solution for injection
INJECTION, SOLUTION
Regulatory Information
SIN13922P
February 24, 2011
Prescription Only
Therapeutic
INTRAMUSCULAR
August 10, 2023
May 30, 2025
XJ07AH08
Company Information
Active Ingredients
Strength: 4 mcg/dose (0.5 ml)
Strength: 4 mcg/dose (0.5 ml)
Strength: 48 mcg/dose (0.5 ml) (Diphtheria toxoid quantity is approximate and dependent on the conjugate polysaccharide to protein ratio)
Strength: 4 mcg/dose (0.5 ml)
Strength: 4 mcg/dose (0.5 ml)
Detailed Information
Contraindications
**CONTRAINDICATIONS** **Hypersensitivity** Severe allergic reaction (e.g., anaphylaxis) after a previous dose of a meningococcal capsular polysaccharide-, diphtheria toxoid- or CRM197-containing vaccine, or to any component of Menactra \[see **DESCRIPTION** – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_\]. **Febrile or Acute Disease** Vaccination should be postponed in case of febrile or acute disease that is moderate or severe. However, a minor febrile or non-febrile illness, such as mild upper respiratory infection, is not usually a valid reason to postpone immunization.
Indication Information
**INDICATIONS AND USAGE** Menactra®, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is indicated for active immunization to prevent invasive meningococcal disease caused by _Neisseria meningitidis_ serogroups A, C, Y and W-135. Menactra is approved for use in individuals 9 months through 55 years of age. Menactra does not prevent _N meningitidis_ serogroup B disease.